中国医药：子公司海南通用康力制药收到药监局关于注射用磷酸特地唑胺签发的《药品注册证书》

Core Viewpoint - China National Pharmaceutical Group announced that its wholly-owned subsidiary, Kangli Pharmaceutical, has received approval from the National Medical Products Administration for the injection of phosphoric acid teicoplanin, expanding the company's product line [1] Group 1: Product Approval - The approved drug is indicated for the treatment of acute bacterial skin and skin structure infections, with a specification of 200mg [1] - The registration application was accepted by the National Medical Products Administration in September 2024, with a total investment of approximately 12.74 million yuan as of the announcement date [1] Group 2: Market Context - A total of 18 manufacturers in China have passed or are deemed to have passed the consistency evaluation for this drug [1] - The estimated sales revenue for public hospitals and grassroots medical terminals in China for this drug is approximately 1.16 million yuan in 2024, indicating a potential market presence [1]